RION
RION is a clinical-stage regenerative medicine company based in Rochester, MN, focused on revolutionizing exosome science to heal from within. Established in 2017, RION leverages the unique properties of exosomes derived from platelets to develop innovative therapies aimed at enhancing tissue regeneration and addressing various medical challenges.
Patents
Particle measuring device, calibration method, and measuring device
2023-10-03 • US-11774340-B2
View DetailsMicrobial particle measuring apparatus and microbial particle measuring method
2022-10-18 • US-11474017-B2
View DetailsViable particle counting system and viable particle counting method
2022-01-04 • US-11215551-B2
View DetailsMicrobial particle counting system and microbial particle counting method
2021-09-14 • US-11119027-B2
View DetailsIn-fluid floating substance measurement flow cell and particle counter
2021-05-18 • US-11009445-B2
View DetailsThree-dimensional shape data production method and three-dimensional shape data production system
2020-12-29 • US-10878563-B2
View DetailsMicroviable particle counting system and microviable particle counting method
2018-10-09 • US-10094763-B2
View DetailsApparatus for counting viable particles in liquid in real time, dialysis fluid monitoring system and purified water monitoring system using the apparatus, and method of counting viable particles in liquid in real time
2016-02-23 • US-9267845-B2
View DetailsParticle counter for measuring floating particles which can effectively reduce false counts
2010-07-13 • US-7755760-B2
View DetailsWhat We Do
A novel ingredient developed by RION, PEP™ is a lyophilized powder containing up to 2 trillion regenerative exosomes per vial, designed to promote tissue regeneration across various applications.
Application Area
Key People
Co-Founder
Co-Founder
Chief Financial Officer
Chief Regulatory Officer
Chief Administrative Officer
Chief Technical Operations
News & Updates
RION received recognition for its innovative contributions to the field of regenerative medicine.
RION has strengthened its leadership team by appointing five experts to its advisory boards.
RION has begun a clinical study to assess the effectiveness of PEP™ in treating knee osteoarthritis.
The company has successfully dosed its first patient in a clinical study targeting diabetic foot ulcers with PEP™.
RION has announced the expansion of its manufacturing capabilities with a new facility in Rochester.